NVNovoCure NVCR · NASDAQ
$14.68 -2.78% (-$0.42)
- Market cap
- $1.73B
- Enterprise value
- $1.87B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -26.2%
- Gross margin
- 76.1%
- Net margin
- -21.2%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.99
- Free float
- 82.8%
About the company
NovoCure Limited is an international biotechnology company specializing in the development of innovative therapies for cancer treatment. The company is known for its unique Tumor Treating Fields (TTFields) technology, which uses electric fields to target and treat tumors, inhibiting their growth. TTFields is a non-invasive treatment that is used for various types of cancer, including brain cancer, lung cancer, and more. NovoCure focuses on providing new therapeutic approaches that can improve treatment outcomes and the quality of life for patients suffering from cancer.
Sector
Healthcare
Industry
Medical - Devices
CEO
Frank Leonard
Employees
1,605
Headquarters
Baar
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number